within Pharmacolibrary.Drugs.ATC.B;

model B05XB01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 30000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B05XB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Arginine hydrochloride is the hydrochloride salt of the essential amino acid L-arginine. It is used clinically as a diagnostic agent for assessing pituitary reserve (e.g., in the evaluation of growth hormone secretion) and as an adjunct to treat metabolic alkalosis or, less commonly, certain urea cycle disorders. It is administered intravenously and is currently approved for specific diagnostic and therapeutic uses.</p><h4>Pharmacokinetics</h4><p>Estimated parameters for healthy adult subjects after single intravenous administration. No explicit published compartmental model parameters found; values are based on pharmacological properties and limited clinical kinetic data for arginine.</p><h4>References</h4><ol><li><p>Garcia, DA, Baglin, TP, Weitz, JI, &amp; Samama, MM (2012). Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> 141(2 Suppl) e24S–e43S. DOI:<a href=&quot;https://doi.org/10.1378/chest.11-2291&quot;>10.1378/chest.11-2291</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22315264/&quot;>https://pubmed.ncbi.nlm.nih.gov/22315264</a></p></li><li><p>Tangphao, O, Grossmann, M, Chalon, S, Hoffman, BB, &amp; Blaschke, TF (1999). Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. <i>British journal of clinical pharmacology</i> 47(3) 261–266. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1999.00883.x&quot;>10.1046/j.1365-2125.1999.00883.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10215749/&quot;>https://pubmed.ncbi.nlm.nih.gov/10215749</a></p></li><li><p>Sotelo, CK, Shropshire, SB, Quimby, J, Simpson, S, Gustafson, DL, &amp; Zersen, KM (2022). Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea. <i>Journal of veterinary pharmacology and therapeutics</i> 45(6) 508–515. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13087&quot;>10.1111/jvp.13087</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35899472/&quot;>https://pubmed.ncbi.nlm.nih.gov/35899472</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B05XB01;
